Department of Internal Medicine, Division of Gastroenterology, Charles A Sammons Cancer Center and Baylor Research Institute, Baylor University Medical Center, Dallas, Texas 75246, USA.
Cancer Res. 2010 Aug 15;70(16):6609-18. doi: 10.1158/0008-5472.CAN-10-0622. Epub 2010 Aug 3.
Global downregulation of microRNAs (miRNA) is a common feature in colorectal cancer (CRC). Whereas CpG island hypermethylation constitutes a mechanism for miRNA silencing, this field largely remains unexplored. Herein, we describe the epigenetic regulation of miR-137 and its contribution to colorectal carcinogenesis. We determined the methylation status of miR-137 CpG island in a panel of six CRC cell lines and 409 colorectal tissues [21 normal colonic mucosa from healthy individuals (N-N), 160 primary CRC tissues and their corresponding normal mucosa (N-C), and 68 adenomas]. TaqMan reverse transcription-PCR and in situ hybridization were used to analyze miR-137 expression. In vitro functional analysis of miR-137 was performed. Gene targets of miR-137 were identified using a combination of bioinformatic and transcriptomic approaches. We experimentally validated the miRNA:mRNA interactions. Methylation of the miR-137 CpG island was a cancer-specific event and was frequently observed in CRC cell lines (100%), adenomas (82.3%), and CRC (81.4%), but not in N-C (14.4%; P < 0.0001 for CRC) and N-N (4.7%; P < 0.0001 for CRC). Expression of miR-137 was restricted to the colonocytes in normal mucosa and inversely correlated with the level of methylation. Transfection of miR-137 precursor in CRC cells significantly inhibited cell proliferation. Gene expression profiling after miR-137 transfection discovered novel potential mRNA targets. We validated the interaction between miR-137 and LSD-1. Our data indicate that miR-137 acts as a tumor suppressor in the colon and is frequently silenced by promoter hypermethylation. Methylation silencing of miR-137 in colorectal adenomas suggests it to be an early event, which has prognostic and therapeutic implications.
miRNA(微小 RNA)在结直肠癌(CRC)中普遍下调。CpG 岛的异常甲基化是 miRNA 沉默的机制之一,但这一领域尚未得到充分研究。在此,我们描述了 miR-137 的表观遗传学调控及其对结直肠发生癌变的贡献。我们在六株 CRC 细胞系和 409 份结直肠组织[21 份来自健康个体的正常结肠黏膜(N-N)、160 份原发性 CRC 组织及其对应的正常黏膜(N-C)和 68 份腺瘤]中测定了 miR-137 CpG 岛的甲基化状态。使用 TaqMan 逆转录-PCR 和原位杂交来分析 miR-137 的表达。进行了 miR-137 的体外功能分析。采用生物信息学和转录组学方法组合来鉴定 miR-137 的基因靶点。我们通过实验验证了 miRNA:mRNA 相互作用。miR-137 CpG 岛的甲基化是一种癌特异性事件,在 CRC 细胞系(100%)、腺瘤(82.3%)和 CRC(81.4%)中经常观察到,但在 N-C(14.4%;CRC 中 P<0.0001)和 N-N(4.7%;CRC 中 P<0.0001)中未观察到。miR-137 的表达局限于正常黏膜的结肠细胞中,与甲基化水平呈负相关。在 CRC 细胞中转染 miR-137 前体可显著抑制细胞增殖。miR-137 转染后的基因表达谱发现了新的潜在 mRNA 靶点。我们验证了 miR-137 和 LSD-1 之间的相互作用。我们的数据表明,miR-137 在结肠中作为一种肿瘤抑制因子发挥作用,并且经常因启动子甲基化而沉默。miR-137 在结直肠腺瘤中的甲基化沉默表明其为早期事件,具有预后和治疗意义。